Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial is currently planned at a single center in Navarra.
Epistemonikos ID: 70a854073c21335f4eca4d411890ce546619c966
First added on: May 16, 2020